217 related articles for article (PubMed ID: 34428992)
1. Cost-effectiveness of lenalidomide plus rituximab versus rituximab monotherapy in patients with previously treated follicular lymphoma: a societal view.
Thielen FW; Kersten MJ; Kuizenga P; Hoogendoorn M; Posthuma EF; Stevens WB; A Uyl-de Groot C; Blommestein HM
Expert Rev Anticancer Ther; 2021 Dec; 21(12):1411-1422. PubMed ID: 34428992
[TBL] [Abstract][Full Text] [Related]
2. Lenalidomide with Rituximab for Previously Treated Follicular Lymphoma and Marginal Zone Lymphoma: An Evidence Review Group Perspective of a NICE Single Technology Appraisal.
Witlox WJA; Grimm SE; Riemsma R; Armstrong N; Ryder S; Duffy S; Carrera VH; Posadzki P; Worthy G; Pouwels XGLV; Ramaekers BLT; Kleijnen J; Joore MA; van Asselt ADI
Pharmacoeconomics; 2021 Feb; 39(2):171-180. PubMed ID: 33145711
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of obinutuzumab plus bendamustine followed by obinutuzumab monotherapy for the treatment of follicular lymphoma patients who relapse after or are refractory to a rituximab-containing regimen in the US.
Guzauskas GF; Masaquel A; Reyes C; Bernaards C; Krivasi T; Veenstra DL
J Med Econ; 2018 Oct; 21(10):960-967. PubMed ID: 29898619
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of Anti-CD19 chimeric antigen receptor T-Cell therapy in pediatric relapsed/refractory B-cell acute lymphoblastic leukemia. A societal view.
Thielen FW; van Dongen-Leunis A; Arons AMM; Ladestein JR; Hoogerbrugge PM; Uyl-de Groot CA
Eur J Haematol; 2020 Aug; 105(2):203-215. PubMed ID: 32289184
[TBL] [Abstract][Full Text] [Related]
5. Lenalidomide plus rituximab Vs rituximab alone in relapsed or refractory indolent lymphoma: A cost-effectiveness analysis.
Zhang PF; Xie D; Wen F; Li Q
Cancer Med; 2020 Aug; 9(15):5312-5319. PubMed ID: 32489014
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of obinutuzumab versus rituximab biosimilars for previously untreated follicular lymphoma.
Spencer SJ; Guzauskas GF; FeLizzi F; Launonen A; Dawson K; Veenstra DL; Masaquel A
J Manag Care Spec Pharm; 2021 May; 27(5):615-624. PubMed ID: 33586513
[No Abstract] [Full Text] [Related]
7. Rituximab for the first-line treatment of stage III-IV follicular lymphoma (review of Technology Appraisal No. 110): a systematic review and economic evaluation.
Papaioannou D; Rafia R; Rathbone J; Stevenson M; Buckley Woods H; Stevens J
Health Technol Assess; 2012; 16(37):1-253, iii-iv. PubMed ID: 23021127
[TBL] [Abstract][Full Text] [Related]
8. Obinutuzumab plus chemotherapy followed by obinutuzumab monotherapy is cost-effective vs. rituximab plus chemotherapy followed by rituximab monotherapy for previously untreated follicular lymphoma patients in the United States.
Guzauskas GF; Masaquel A; Thuresson PO; Dawson K; Veenstra DL
Leuk Lymphoma; 2019 Jul; 60(7):1668-1676. PubMed ID: 30632837
[TBL] [Abstract][Full Text] [Related]
9. Cost-Effectiveness of Venetoclax Plus Obinutuzumab Versus Chlorambucil Plus Obinutuzumab for the First-Line Treatment of Adult Patients With Chronic Lymphocytic Leukemia: An Extended Societal View.
Do N; Thielen FW
Value Health; 2023 Apr; 26(4):477-486. PubMed ID: 36375678
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of mosunetuzumab for treatment of relapsed or refractory follicular lymphoma after two or more lines of systemic therapy in the United States.
Matasar M; Sanchez Alvarez J; Parisé H; Zuk E; Di Maio D; Shapouri S; Kim E; Lin SW
J Med Econ; 2024; 27(1):766-776. PubMed ID: 38712895
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness analysis of treatment regimens with obinutuzumab plus chemotherapy in Japan for untreated follicular lymphoma patients.
Ohno S; Shoji A; Hatake K; Oya N; Igarashi A
J Med Econ; 2020 Oct; 23(10):1130-1141. PubMed ID: 32620061
[TBL] [Abstract][Full Text] [Related]
12. Obinutuzumab in Combination with Chemotherapy for the First-Line Treatment of Patients with Advanced Follicular Lymphoma : An Evidence Review Group Evaluation of the NICE Single Technology Appraisal.
Thielen FW; Büyükkaramikli NC; Riemsma R; Fayter D; Armstrong N; Wei CY; Huertas Carrera V; Misso K; Worthy G; Kleijnen J; Corro Ramos I
Pharmacoeconomics; 2019 Aug; 37(8):975-984. PubMed ID: 30547368
[TBL] [Abstract][Full Text] [Related]
13. Cost-effectiveness of maintenance rituximab treatment after second line therapy in patients with follicular lymphoma in Sweden.
Kasteng F; Erlanson M; Hagberg H; Kimby E; Relander T; Lundkvist J
Acta Oncol; 2008; 47(6):1029-36. PubMed ID: 18607857
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of adding transarterial chemoembolisation to lenvatinib as first-line treatment for advanced hepatocellular carcinoma in China.
Li W; Wan L
BMJ Open; 2023 Sep; 13(9):e074245. PubMed ID: 37751954
[TBL] [Abstract][Full Text] [Related]
15. Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway.
Haukaas FS; Ohna A; Krivasi T
Appl Health Econ Health Policy; 2018 Aug; 16(4):569-577. PubMed ID: 29923173
[TBL] [Abstract][Full Text] [Related]
16. An evaluation of the cost-effectiveness of rituximab in combination with chemotherapy for the first-line treatment of follicular non-Hodgkin's lymphoma in the UK.
Ray JA; Carr E; Lewis G; Marcus R
Value Health; 2010; 13(4):346-57. PubMed ID: 20070643
[TBL] [Abstract][Full Text] [Related]
17. Cost-Effectiveness Analysis of Bendamustine Plus Rituximab as a First-Line Treatment for Patients with Follicular Lymphoma in Spain.
Sabater E; López-Guillermo A; Rueda A; Salar A; Oyagüez I; Collar JM
Appl Health Econ Health Policy; 2016 Aug; 14(4):465-477. PubMed ID: 27090915
[TBL] [Abstract][Full Text] [Related]
18. [Economic analysis of rituximab in combination with cyclophosphamide, vincristine and prednisolone in the treatment of patients with advanced follicular lymphoma in Portugal].
Braga P; Carvalho S; Gomes M; Guerra L; Lúcio P; Marques H; Negreiro F; Pereira C; Silva C; Teixeira A
Acta Med Port; 2010; 23(6):1025-34. PubMed ID: 21627880
[TBL] [Abstract][Full Text] [Related]
19. Cost-Effectiveness Analysis of Tisagenlecleucel for the Treatment of Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma in the United States.
Qi CZ; Bollu V; Yang H; Dalal A; Zhang S; Zhang J
Clin Ther; 2021 Aug; 43(8):1300-1319.e8. PubMed ID: 34380609
[TBL] [Abstract][Full Text] [Related]
20. A cost-effectiveness analysis of front-line treatment strategies in early-stage follicular lymphoma.
Tobin JWD; Crothers A; Ma TE; Mollee P; Gandhi MK; Scuffham P; Hapgood G
Leuk Lymphoma; 2021 Dec; 62(14):3484-3492. PubMed ID: 34323129
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
